These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 26883273)

  • 21. Identification of an aberrantly spliced form of HDMX in human tumors: a new mechanism for HDM2 stabilization.
    Giglio S; Mancini F; Gentiletti F; Sparaco G; Felicioni L; Barassi F; Martella C; Prodosmo A; Iacovelli S; Buttitta F; Farsetti A; Soddu S; Marchetti A; Sacchi A; Pontecorvi A; Moretti F
    Cancer Res; 2005 Nov; 65(21):9687-94. PubMed ID: 16266988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Loss of HAUSP-mediated deubiquitination contributes to DNA damage-induced destabilization of Hdmx and Hdm2.
    Meulmeester E; Maurice MM; Boutell C; Teunisse AF; Ovaa H; Abraham TE; Dirks RW; Jochemsen AG
    Mol Cell; 2005 May; 18(5):565-76. PubMed ID: 15916963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. HdmX stimulates Hdm2-mediated ubiquitination and degradation of p53.
    Linares LK; Hengstermann A; Ciechanover A; Müller S; Scheffner M
    Proc Natl Acad Sci U S A; 2003 Oct; 100(21):12009-14. PubMed ID: 14507994
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vivo activation of the p53 tumor suppressor pathway by an engineered cyclotide.
    Ji Y; Majumder S; Millard M; Borra R; Bi T; Elnagar AY; Neamati N; Shekhtman A; Camarero JA
    J Am Chem Soc; 2013 Aug; 135(31):11623-11633. PubMed ID: 23848581
    [TBL] [Abstract][Full Text] [Related]  

  • 25. HDM2 antagonist Nutlin-3 disrupts p73-HDM2 binding and enhances p73 function.
    Lau LM; Nugent JK; Zhao X; Irwin MS
    Oncogene; 2008 Feb; 27(7):997-1003. PubMed ID: 17700533
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Allosteric Interactions by p53 mRNA Govern HDM2 E3 Ubiquitin Ligase Specificity under Different Conditions.
    Medina-Medina I; García-Beltrán P; de la Mora-de la Mora I; Oria-Hernández J; Millot G; Fahraeus R; Reyes-Vivas H; Sampedro JG; Olivares-Illana V
    Mol Cell Biol; 2016 Aug; 36(16):2195-205. PubMed ID: 27215386
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A small-molecule inhibitor of MDMX activates p53 and induces apoptosis.
    Wang H; Ma X; Ren S; Buolamwini JK; Yan C
    Mol Cancer Ther; 2011 Jan; 10(1):69-79. PubMed ID: 21075910
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DIMP53-1: a novel small-molecule dual inhibitor of p53-MDM2/X interactions with multifunctional p53-dependent anticancer properties.
    Soares J; Espadinha M; Raimundo L; Ramos H; Gomes AS; Gomes S; Loureiro JB; Inga A; Reis F; Gomes C; Santos MMM; Saraiva L
    Mol Oncol; 2017 Jun; 11(6):612-627. PubMed ID: 28296148
    [TBL] [Abstract][Full Text] [Related]  

  • 29. HDMX regulates p53 activity and confers chemoresistance to 3-bis(2-chloroethyl)-1-nitrosourea.
    Jin G; Cook S; Cui B; Chen WC; Keir ST; Killela P; Di C; Payne CA; Gregory SG; McLendon R; Bigner DD; Yan H
    Neuro Oncol; 2010 Sep; 12(9):956-66. PubMed ID: 20472715
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage.
    Pereg Y; Lam S; Teunisse A; Biton S; Meulmeester E; Mittelman L; Buscemi G; Okamoto K; Taya Y; Shiloh Y; Jochemsen AG
    Mol Cell Biol; 2006 Sep; 26(18):6819-31. PubMed ID: 16943424
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Synergistic growth inhibition based on small-molecule p53 activation as treatment for intraocular melanoma.
    de Lange J; Ly LV; Lodder K; Verlaan-de Vries M; Teunisse AF; Jager MJ; Jochemsen AG
    Oncogene; 2012 Mar; 31(9):1105-16. PubMed ID: 21765463
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structural States of Hdm2 and HdmX: X-ray Elucidation of Adaptations and Binding Interactions for Different Chemical Compound Classes.
    Kallen J; Izaac A; Chau S; Wirth E; Schoepfer J; Mah R; Schlapbach A; Stutz S; Vaupel A; Guagnano V; Masuya K; Stachyra TM; Salem B; Chene P; Gessier F; Holzer P; Furet P
    ChemMedChem; 2019 Jul; 14(14):1305-1314. PubMed ID: 31066983
    [TBL] [Abstract][Full Text] [Related]  

  • 33. RNAi knockdown of HdmX or Hdm2 leads to new insights into p53 signaling.
    Berberich SJ
    Cell Cycle; 2010 Sep; 9(18):3640-1. PubMed ID: 20855947
    [No Abstract]   [Full Text] [Related]  

  • 34. Phosphorylation of Hdmx mediates its Hdm2- and ATM-dependent degradation in response to DNA damage.
    Pereg Y; Shkedy D; de Graaf P; Meulmeester E; Edelson-Averbukh M; Salek M; Biton S; Teunisse AF; Lehmann WD; Jochemsen AG; Shiloh Y
    Proc Natl Acad Sci U S A; 2005 Apr; 102(14):5056-61. PubMed ID: 15788536
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Alternate splicing of the p53 inhibitor HDMX offers a superior prognostic biomarker than p53 mutation in human cancer.
    Lenos K; Grawenda AM; Lodder K; Kuijjer ML; Teunisse AF; Repapi E; Grochola LF; Bartel F; Hogendoorn PC; Wuerl P; Taubert H; Cleton-Jansen AM; Bond GL; Jochemsen AG
    Cancer Res; 2012 Aug; 72(16):4074-84. PubMed ID: 22700878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Implementation of a 220,000-compound HCS campaign to identify disruptors of the interaction between p53 and hDM2 and characterization of the confirmed hits.
    Dudgeon DD; Shinde S; Hua Y; Shun TY; Lazo JS; Strock CJ; Giuliano KA; Taylor DL; Johnston PA; Johnston PA
    J Biomol Screen; 2010 Aug; 15(7):766-82. PubMed ID: 20639499
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Beta-peptides with improved affinity for hDM2 and hDMX.
    Harker EA; Daniels DS; Guarracino DA; Schepartz A
    Bioorg Med Chem; 2009 Mar; 17(5):2038-46. PubMed ID: 19211253
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mouse double minute antagonist Nutlin-3a enhances chemotherapy-induced apoptosis in cancer cells with mutant p53 by activating E2F1.
    Ambrosini G; Sambol EB; Carvajal D; Vassilev LT; Singer S; Schwartz GK
    Oncogene; 2007 May; 26(24):3473-81. PubMed ID: 17146434
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Inhibition of Wild-Type p53-Expressing AML by the Novel Small Molecule HDM2 Inhibitor CGM097.
    Weisberg E; Halilovic E; Cooke VG; Nonami A; Ren T; Sanda T; Simkin I; Yuan J; Antonakos B; Barys L; Ito M; Stone R; Galinsky I; Cowens K; Nelson E; Sattler M; Jeay S; Wuerthner JU; McDonough SM; Wiesmann M; Griffin JD
    Mol Cancer Ther; 2015 Oct; 14(10):2249-59. PubMed ID: 26206331
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In Silico Improvement of beta3-peptide inhibitors of p53 x hDM2 and p53 x hDMX.
    Michel J; Harker EA; Tirado-Rives J; Jorgensen WL; Schepartz A
    J Am Chem Soc; 2009 May; 131(18):6356-7. PubMed ID: 19415930
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.